Saturday 17 October 2026
Export SVA’s income statement to Excel — free account
Sinovac Biotech, Ltd.
Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.
6.47
0.00
0.00%
Follow SVA
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.19 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 0.06 | |
P/FCF ratio |
— | — | — | 0.14 | |
P/Operating CF |
— | — | — | (16.18) | |
P/B ratio |
— | — | — | 0.05 | |
Price to Tangible BV |
— | — | — | 0.05 | |
EV/Sales |
— | — | — | (1.02) | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (1.83) | |
EV/FCF |
— | — | — | (2.17) | |
Quick Ratio |
5.95 | 2.05 | 11.22 | 9.73 | |
Current Ratio |
6.07 | 2.07 | 11.39 | 9.89 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
4.68% | 3.74% | 2.40% | 1.55% | |
Debt/Equity |
0.06 | 0.07 | 0.03 | 0.02 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.76 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | (2.86) | |
Capex/Depreciation |
(0.44) | (0.55) | (0.84) | 0.00 | |
Interest Coverage |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 107.86% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 165.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Graham Net Nets |
— | — | — | 15.89 | |
Graham Number |
— | — | — | 307.63 | |
Earnings Yield |
— | — | — | 531.22% | |
Free Cash Flow Yield |
— | — | — | 727.69% | |
Revenue per Share |
— | — | — | 1.40 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | (0.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(341.49) | (337.18) | (495.90) | (92.90) | |
Working Capital |
5,533.25 | 5,375.38 | 10,169.83 | 10,579.40 | |
Capital Expenditures |
(19.72) | (26.53) | (57.01) | (92.90) | |
Net Current Asset Value |
4,950.53 | 4,733.20 | 9,758.34 | 10,281.28 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | — | 3.00 | |
| Other line items | |||||
Average Receivables |
451.66 | 645.90 | 678.36 | 946.72 | |
Average Payables |
135.11 | 462.07 | 350.29 | 889.27 | |
Average Inventory |
143.81 | 188.07 | 264.76 | 295.37 | |
Average Assets |
11,126.89 | 13,526.54 | 14,825.97 | 13,180.01 | |
Average Common Equity |
7,692.95 | 7,905.74 | 10,420.99 | 9,058.62 |
Columns are period end dates